Trial · NCT03192176
Outcomes36
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 36
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 | Baseline and week 4 | FAS population with available data at specified time point. | VMS per day | LEAST_SQUARES_MEAN |
| PRIMARY | Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12 | Baseline and week 12 | FAS population with available data at specified time point. | VMS per day | LEAST_SQUARES_MEAN |
| PRIMARY | Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4 | Baseline and week 4 | FAS population with available data at specified time point. | Score on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12 | Baseline and week 12 | FAS population with available data at specified time point. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in The Mean Frequency of Mild, Moderate, and Severe VMS to Each Study Week | Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | VMS per day | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in The Mean Frequency of Moderate and Severe VMS to Each Study Week | Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15 | FAS population with available data at specified time point. | VMS per day | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in The Mean Severity of Mild, Moderate, and Severe VMS to Each Study Week | Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in The Mean Severity of Moderate and Severe VMS to Each Study Week | Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15 | FAS population with available data at specified time point. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in The Hot Flash Score of Mild, Moderate, and Severe VMS to Each Study Week | Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in The Hot Flash Score of Moderate and Severe VMS to Each Study Week | Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Percent Reduction of Mild, Moderate, And Severe Vasomotor Symptoms From Baseline to Each Study Week | Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | Percent Reduction | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Percent Reduction of Moderate And Severe Vasomotor Symptoms From Baseline to Each Study Week | Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | Percent Reduction | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week | Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15 | FAS population with available data at specified time point. | participants | NUMBER |
| SECONDARY | Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week | Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | participants | NUMBER |
| SECONDARY | Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week | Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | participants | NUMBER |
| SECONDARY | Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week | Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | participants | NUMBER |
| SECONDARY | Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week | Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | participants | NUMBER |
| SECONDARY | Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week | Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | participants | NUMBER |
| SECONDARY | Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week | Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | participants | NUMBER |
| SECONDARY | Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week | Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 | FAS population with available data at specified time point. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03192176/outcomes